申请人:Allergan, Inc.
公开号:US20160102077A1
公开(公告)日:2016-04-14
This invention is directed to a compound of Formula I
or a pharmaceutically acceptable salt thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
这项发明涉及到化合物I的一种或其药用可接受的盐,其中R1、R2、R3、R4、R5、R6、R7、R8、R9和X的定义如本文所述。化合物I的用途是作为受体酪氨酸激酶(RTK)抑制剂,可用于治疗癌症、血管增殖性疾病、纤维化疾病、系膜细胞增殖性疾病和代谢性疾病。